Development and validation of a score to assess complexity of general internal medicine patients at hospital discharge: a prospective cohort study. by Liechti, Fabian D. et al.
1Liechti FD, et al. BMJ Open 2021;11:e041205. doi:10.1136/bmjopen-2020-041205
Open access 
Development and validation of a score 
to assess complexity of general internal 
medicine patients at hospital discharge: 
a prospective cohort study
Fabian D Liechti   ,1 Thomas Beck,1 Adrian Ruetsche,2 Marie C Roumet,3 
Andreas Limacher,3 Tobias Tritschler   ,1,4 Jacques D Donzé1,5,6,7
To cite: Liechti FD, Beck T, 
Ruetsche A, et al.  Development 
and validation of a score to 
assess complexity of general 
internal medicine patients at 
hospital discharge: a prospective 
cohort study. BMJ Open 
2021;11:e041205. doi:10.1136/
bmjopen-2020-041205
 ► Prepublication history and 
additional online supplemental 
material for this paper are 
available online. To view these 
files, please visit the journal 
online (http:// dx. doi. org/ 10. 
1136/ bmjopen- 2020- 041205).
Received 03 June 2020
Revised 16 April 2021
Accepted 19 April 2021
For numbered affiliations see 
end of article.
Correspondence to
Dr Fabian D Liechti;  
 fabian. liechti@ insel. ch
Original research
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
ABSTRACT
Objective We aimed to develop and validate a score to 
assess inpatient complexity and compare its performance 
with two currently used but not validated tools to estimate 
complexity (ie, Charlson Comorbidity Index (CCI), patient 
clinical complexity level (PCCL)).
Methods Consecutive patients discharged from the 
department of medicine of a tertiary care hospital were 
prospectively included into a derivation cohort from 1 
October 2016 to 16 February 2017 (n=1407), and a 
temporal validation cohort from 17 February 2017 to 31 
March 2017 (n=482). The physician in charge assessed 
complexity. Potential predictors comprised 52 parameters 
from the electronic health record such as health factors 
and hospital care usage. We fit a logistic regression model 
with backward selection to develop a prediction model and 
derive a score. We assessed and compared performance 
of model and score in internal and external validation using 
measures of discrimination and calibration.
Results Overall, 447 of 1407 patients (32%) in the 
derivation cohort, and 116 of 482 patients (24%) in the 
validation cohort were identified as complex. Eleven 
variables independently associated with complexity were 
included in the score. Using a cut- off of ≥24 score points 
to define high- risk patients, specificity was 81% and 
sensitivity 57% in the validation cohort. The score’s area 
under the receiver operating characteristic (AUROC) curve 
was 0.78 in both the derivation and validation cohort. In 
comparison, the CCI had an AUROC between 0.58 and 
0.61, and the PCCL between 0.64 and 0.69, respectively.
Conclusions We derived and internally and externally 
validated a score that reflects patient complexity in the 
hospital setting, performed better than other tools and 
could help monitoring complex patients.
INTRODUCTION
One- fourth of patients are estimated to 
be complex in the primary care setting, 
while this proportion is not well known 
in the hospital setting.1–4 Generally, those 
patients using more resources, time and/
or effort are regarded as complex patients, 
although no universal definition of patient 
complexity is available. Complexity is not 
limited to multimorbidity and chronicity of 
disease but depends also on multiple other 
aspects, including psychological, social, 
economic and environmental factors.1 2 5–7 
Complex patients challenge the current 
structures, for example, they have a higher 
probability of future emergency department 
utilisation (without higher mortality rates) 
and show suboptimal use of the healthcare 
system.2 8–10 Identifying complex patients 
is of economic, epidemiological and social 
importance because it may help to better 
allocate resources and improve healthcare 
utilisation.5 11
The only available assessment method 
to identify complex inpatients is currently 
the physician’s assessment, which limits 
the monitoring of patient complexity over 
time.10 12 13 The Charlson Comorbidity Index 
(CCI), originally developed and validated 
to predict mortality,14 has been assessed as a 
proxy for patient complexity in the primary 
care setting. However, agreement between 
Strengths and limitations of this study
 ► This is a prospective cohort study of consecutive, 
unselected, adult inpatients discharged from the de-
partment of medicine of a large university hospital.
 ► We derived and validated an easily usable score that 
accurately assesses patient complexity in medical 
inpatients that may help monitoring the proportion of 
complex patients (Patient Complexity Assessement 
(PCA) score).
 ► The reference standard used to define complexity 
was the physician’s judgement, which per definition 
is partly subjective.
 ► The PCA score has been developed at a single tertia-
ry hospital and may not consider a comprehensive 
list of important indicators.
 ► The PCA score includes values available only at dis-
charge and indicators are not modifiable.
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Table 1 Baseline characteristics for all patients (derivation and validation cohort) stratified by complexity, as number and 






n (%) or median (IQR)
Age
  ≥80 years 579 (31) 442 (33) 137 (24)
  70–79 years 437 (23) 304 (23) 133 (24)
  60–69 years 322 (17) 211 (16) 111 (20)
  <60 years 537 (28) 363 (27) 174 (31)
  Missing 14 (0.7) 6 (0.5) 8 (1.4)
Gender
  Male 1002 (53) 693 (52) 309 (55)
  Female 873 (46) 627 (47) 246 (44)
  Missing 14 (0.7) 6 (0.5) 8 (1)
Living area*
  Urban 611 (32) 453 (34) 158 (28)
  Rural 1238 (65) 848 (64) 390 (69)
  Missing 40 (2) 25 (1) 15 (3)
Marital status
  Single 331 (17) 252 (19) 79 (14)
  Couple 636 (34) 429 (32) 207 (37)
  Widowed 916 (48) 641 (48) 275 (49)
  Missing 6 (0.3) 4 (0.3) 2 (0.4)
Hospitalisation within last 12 months 673 (36) 452 (34) 221 (39)
Medication†
  Antineoplastic and immunomodulating agents, at 
admission
70 (4) 38 (3) 32 (6)
  Nervous system, at admission 1340 (71) 918 (69) 422 (75)
  Systemic hormonal preparations, excluding sex 
hormones and insulins, at discharge
524 (28) 318 (24) 206 (37)
High costs during hospitalisation‡
  For imaging procedures 485 (26) 255 (19) 230 (41)
  For laboratory analysis 482 (25) 203 (15) 279 (50)
High nurse workload§ 475 (25) 203 (15) 272 (48)
Charlson Comorbidity Index 2(0; 4) 2(0; 3) 3(1 5)
Principal or concomitant diagnosis at discharge
  Cancer¶ 225 (12) 136 (10) 89 (16)
  COPD** 186 (10) 124 (9) 62 (11)
  Dementia†† 163 (9) 125 (9) 38 (7)
  Depression‡‡ 209 (11) 140 (11) 69 (12)
  Heart failure§§ 327 (17) 206 (15) 121 (21)
  Pneumonia†††† 244 (13) 159 (12) 85 (15)
  Sepsis¶¶ 229 (12) 132 (10) 97 (17)
  Stroke*** 90 (5) 65 (5) 25 (4)
  Substance abuse††† 212 (11) 129 (10) 83 (15)
  Syncope‡‡‡ 81 (4) 67 (5) 14 (2)
  Malnutrition§§§ 265 (14) 122 (9) 143 (25)
Multimorbidity
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the primary care physician’s assessment and the CCI 
to identify complex patients was only modest.1 2 5 No 
such assessment has been yet performed in the hospital 
setting. The patient clinical complexity level (PCCL) is 
calculated for each treatment episode to indicate the 
effect of complications and comorbidities in a patient. 
The PCCL ranges from 0 (no complication or comor-
bidity) to 4 (very severe complication or comorbidity), 
according to a complex algorithm.14 15 Identification 
of complex patients at discharge could help to identify 
those, who would profit from more intense follow- up, 






n (%) or median (IQR)
  Middle (no of diagnoses >6 and <14)‡‡‡‡ 841 (44) 603 (45) 238 (42)
  High (no of diagnoses ≥14) 524 (28) 282 (21) 242 (43)
PCCL 3(2 4) 3(1 4) 4(3 4)
  No complication or comorbidity 380 (20) 312 (23) 68 (12)
  Light complication or comorbidity 29 (1) 21 (2) 8 (1)
  Moderate complication or comorbidity 292 (15) 233 (18) 59 (10)
  Severe complication or comorbidity 533 (28) 409 (31) 124 (22)
  Very severe complication or comorbidity 641 (34) 345 (26) 296 (53)
  Missing 14 (0.7) 6 (0.5) 8 (1.4)
Abnormal creatinine level (creatinine ≥100 µmol/L)
  At admission and discharge 368 (19) 241 (18) 127 (23)
  At admission only 182 (10) 106 (8) 76 (13)
  At discharge only 63 (3) 34 (3) 29 (5)
  Missing 364 (19) 311 (23) 53 (9)
Leucocytosis (leucocyte count ≥20 G/L)
  At admission and discharge 77 (41) 47 (3) 30 (5)
  At admission only 19 (1) 8 (<1) 11 (2)
  At discharge only 13 (<1) 5 (<1) 8 (1)
  Missing 351 (19) 306 (23) 45 (8)
Patient destination
  Death 134 (7) 91 (7) 43 (8)
  Home 1178 (62) 873 (66) 305 (54)
  Hospital 191 (10) 119 (9) 72 (13)
  Nursing home 155 (8) 108 (8) 47 (8)
  Rehabilitation 171 (9) 101 (8) 70 (12)
  Others and missing 60 (3) 24 (3) 26 (5)
*Defined according to the Swiss Federal Statistical Office based on place of residence.
†Group of drugs according to ATC classification.
‡Defined as costs of all imaging procedures or laboratory analysis (without microbiology) during hospital stay above 75th percentile.
§Defined as sum of hours of all nursing work (including sitting guard) during hospital stay above 75th percentile.
¶ICD10- codes B21, C00 through C97, Z03.1.
**ICD10- codes J44.
††ICD10- codes F00 through F03, F05.0, F05.1.
‡‡ICD10- codes F20.4, F25.1, F31.3 F31.4, F31.5, F32, F33, F41.2, F92.0.
§§ICD10- codes I50.
¶¶ICD10- codes A02.1, A20.7, A22.7, A26.7, A32.7, A39.2, A39.3, A39.4, A40, A41, A42.7, B37.7.
***ICD10- codes I63.
†††ICD10- codes F10 through F19.
‡‡‡ICD10- codes R55.
§§§ICD10- codes E40 through E46.
¶¶¶Defined as creatinine ≥100 µmol/L.
****Defined as leucocyte count ≥20 G/L.
††††ICD10- codes A48.1, B01.2, B05.2, J10.0, J11.0, J12 through J18, J68.0, J69, J85.1, O74.0, U69.00.
‡‡‡‡Between 25th and 75th percentile.
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although effectiveness of such interventions would have 
to be proven first.
In order to simplify and standardise the identifica-
tion of complex patients, we aimed to develop and vali-
date a new score to help identifying the most complex 
inpatients (Patient Complexity Assessment, PCA score) 
using readily available administrative and clinical data. 
Our hypothesis was that some data routinely collected 
during a hospitalisation can be used as a valuable surro-
gate to physician’s assessment. We then compared the 
performance of the newly developed PCA score to the 
CCI, and the PCCL used in the Swiss DRG system to allo-
cate reimbursement according to multimorbidity.14 15
METHODS
Study design and participants
This study was a prospective cohort of consecutive, unse-
lected, adult inpatients discharged from the department 
of medicine of a large University hospital (Inselspital, 
Bern University Hospital, Bern, Switzerland) between 1 
October 2016 and 31 March 2017. The only exclusion 
criterion was a previous study inclusion. We originally 
planned to consider around 35 variables in the predic-
tion model. With an estimated proportion of complex 
patients of one fourth, we preset the sample size of 
the derivation cohort to be 1400 (rule of thumb of 10 
outcomes per variable tested).16 17 We predefined, that if 
more than 1400 patients will be included during the study 
period of 6 months, we would use these patients to exter-
nally validate the prediction model. Patients enrolled 
before 16 February 2017 were allocated to the deriva-
tion sample (derivation and internal validation cohort), 
and patients enrolled after this date were allocated to an 
external validation sample (temporal validation cohort). 
During their first admission, all patients included in the 
study gave their written general consent to the use of 
their routine data for research purposes. We reported the 
study in accordance with the Transparent Reporting of a 
Multivariable Prediction Model for Individual Prognosis 
Or Diagnosis statement.18
Patient and public involvement
No patient involved.
Study outcome and predictor variables
The primary outcome was the predictive accuracy of the 
PCA against the treating physician’s judgement as the 
gold standard to identify complex general internal medi-
cine inpatients. Complex patients were defined as those 
using more resources, time and/or effort while hospital-
ised. The resident (or supervising consultant) was asked 
by a trained study nurse to assess at time of discharge 
the level of complexity of the entire hospital stay of her/
his patient without providing any specific scoring system 
(complex or not- complex).
The CCI was originally developed to predict 10- year 
survival by using an algorithm based on addition of score 
points for specific diagnoses.14 19 The PCCL was derived 
from the electronic health record (no complication or 
comorbidity: 0; light complication or comorbidity: 1; 
moderate complication or comorbidity: 2; severe compli-
cation or comorbidity: 3; very severe complication or 
comorbidity: 4 and is defined by SwissDRG.20 21
For all patients, information regarding International 
Classification of Disease (ICD) codes and other poten-
tial indicators for patient complexity were collected 
retrospectively through the electronic health record of 
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the hospital. Candidate predictor variables have been 
selected based on a previous survey among general inter-
nists in the hospital setting which asked them to identify 
factors that contribute to patient complexity,4 and on a 
selection of readily available potential predictors to have 
a broad spectrum of candidate predictors. Variables that 
were not routinely collected were removed (ie, variables 
with more than 25% missing data, such as aspartate amino 
transferase, C reactive protein and albumin at discharge). 
Collinearity between variables was assessed using Pearson 
correlation coefficients. In case of strong correlation 
(r>0.7), only the strongest univariate predictor was kept. 
A final list of 52 indicators was considered in denoting 
complexity: baseline demographic information (age, 
gender, living area (rural vs urban, defined according to 
the Swiss Federal Statistical Office based on the patient’s 
place of residence), marital status, institutional care before 
admission, nationality (Swiss vs non- Swiss), hospital vari-
ables (urgent vs elective admission, number of previous 
hospitalisation in the last 12 months, patient destination 
(death, home, other hospital, nursing home, rehabil-
itation, other), stay on the intensive care unit, internal 
transfer), drugs (for each group of the Anatomical, Ther-
apeutic and Chemical classification categories) at admis-
sion and at discharge and polypharmacy (≥10 drugs,22 
at admission and discharge), main diagnosis (cancer, 
chronic obstructive pulmonary disease, dementia, depres-
sion, heart failure, pneumonia, sepsis, stroke, substance 
abuse, syncope, malnutrition, based on the 10th Revi-
sion of the ICD and Related Health Problems code), 
number of diagnoses at discharge, CCI, laboratory values 
(haemoglobin, leucocyte count and thrombocyte count, 
serum sodium and creatinine) at admission (first lab 
values at admission) and discharge (last lab values before 
discharge), number of interventions and costs (normal 
vs high costs, ie, ≥ the 75th empirical percentile value) 
during hospitalisation of blood products, drugs, imaging 
procedures, physiotherapy and nursing workload.
Missing data
When missing, the value of haemoglobin and creatinine 
at discharge was assumed to be identical to the value 
at admission. When missing, the value of sodium and 
platelet count at discharge was considered normal. For 
other potential indicators of complexity, we assumed data 
to be missing at random and imputed missing data using 
single imputation by chained equations. To compare 
performance measures of the PCA with the CCI and 
PCCL, patients with missing values for the PCCL variable 
(n=3 for the derivation, n=11 for the validation dataset) 
were removed prior to analysis.
Statistical analysis
Multivariable logistic regression analysis with back-
ward selection was used in the derivation set to predict 
complexity based on 52 potential indicators of complexity 
variables registered during hospitalisation, removing vari-
ables with a p>0.1. Calibration of the final model was 
evaluated by constructing a calibration curve, estimating 
the calibration slope, calculating the difference between 
the mean observed proportion and mean predicted 
proportion of patients with high complexity (calibration- 
in- the- large) and the Brier score (overall measure of 
accuracy) in the derivation and validation set. The predic-
tors from the final model were used to create a compre-
hensible score using the regression coefficient- based 
scoring technique.23 Beta- coefficients were divided by the 
lowest coefficient and rounded up to the closest integer 
to generate score points, indicating increasing risk by 
higher scores. The discriminatory power of the score was 
assessed by calculating the area under the receiver oper-
ating characteristic (AUROC) curve.
The validity of performance measures was investi-
gated by performing internal and external validation. 
For internal validation we used 1000 bootstrap samples, 
drawing samples with replacement from the derivation 
sample.24 The bootstrap- corrected performance esti-
mates were calculated by subtracting the optimism from 
the performance of the original model. The 95% CIs for 
the bootstrapped performance measures were derived 
using the percentile method. External validation was 
made by estimating the same performance measures in 
the external validation cohort (temporal validation).
The clinical usefulness of the developed score was 
assessed with a decision- curve analysis investigating 
whether the use of the complexity score instead of the 
CCI alone was associated with benefit gains relative to the 
prediction complexity.25
Applying PCA, CCI and PCCL, we calculated the score 
of each patient and split the patient sample into a high- 
risk and a low- risk group. The reference point (cut- off) 
of each scoring system was chosen in order to make the 
frequency of patients in the high- risk category as close 
as possible to 30% (ie, approximating the frequency of 
observed complex patients). To determine the accuracy 
of this method to predict complexity, we estimated sensi-
tivity, specificity and positive and negative predictive value 
in both the derivation and validation set for PCA and in 
the derivation set for CCI and PCCL.
R V.3.3.1 was used for statistical analysis.
RESULTS
A total of 1889 patients were included in the study 
(figure 1). Patients enrolled before 16 February 2017 
were allocated to the derivation sample (n=1407), 
patients enrolled after this date (n=482) were allocated to 
the temporal validation sample. In the derivation cohort, 
447 patients (31.8%) were clinically judged as complex 
and 116 (24.1%) patients in the validation cohort. The 
patients in the two cohorts presented with similar base-
line characteristics (table 1 and online supplemental 
material table S1 and S2). The overall median age was 80 
years (IQR 75–86 years).
After backward selection, 11 of the 52 potential predic-
tors were used to derive the PCA score (table 2). Besides 
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diagnosis- related factors, they represented demographic 
characteristic, hospital variables, medication and labora-
tory values. Highest score points were assigned to leuco-
cytosis (at discharge only, 16 points and at admission and 
discharge, 10 points) followed by age under 60 years, high 
nurse workload (costs above 75th percentile for nursing 
expenses), and abnormal serum creatinine at discharge 
(≥100 µmol/L).
The prediction model showed a good accuracy, with 
a Brier score of 0.17 and 0.15 in internal and external 
validation, respectively. The calibration curve showed 
fair agreement between predicted and observed propor-
tions of complexity in the derivation cohort and slightly 
lower observed proportions than predicted probabili-
ties in the validation cohort (graphs not shown). The 
calibration- in- the- large coefficient of −0.51 (95% CI 
−0.74 to −0.27) in the validation cohort implies that the 
mean observed proportion was lower than the mean 
predicted probability. However, the calibration curve 
slope was satisfactory in internal and external validation 
(0.93 (95% CI 0.80 to 1.05) and 0.96 (95% CI 0.74 to 
1.18)), respectively.
The median score was 17 points in the derivation and 
validation cohort (mean 18.77 and 19.03, respectively). 
The minimal score was 0 points in both cohorts, the 
maximal score reached was 54 points in the derivation 
cohort and 53 points in the validation cohort (theoreti-
cally maximal 81 score points). The score’s AUROC curve 
was 0.77 (95% CI 0.74 to 0.79) and 0.78 (95% CI 0.74 to 
0.82) in internal and external validation.
We classified patients as low and high complexity risk 
(table 3) according to the selected cut- off of 24 points 
(approximating the frequency of observed complex 
patients of 30%). The proportion of patients categorised 
as complex (ie, score ≥24 points) was 30% and 28% in 
the derivation and validation dataset, respectively. Sensi-
tivity was 57% in both the derivation and validation 
dataset. The specificity was 83% and 81%, respectively. 
Positive predictive values were 61% and 49% in the deri-
vation and validation cohort, respectively, while negative 
predictive values were 81% and 86%, respectively. The 
discriminatory power of the PCA score was robust with an 
AUROC of 0.77 (95% CI 0.74 to 0.79) in internal valida-
tion (bootstrap- corrected value) and 0.78 (95% CI 0.74 
to 0.82) in external validation (table 4 and online supple-
mental figure S2).
In comparison, predictive accuracy of the CCI was 
lower compared with the PCA score. The AUROCs were 
low with 0.58 (95% CI 0.55 to 0.62) and 0.62 (95% CI 0.56 
to 0.68) in the derivation and validation cohort, respec-
tively (table 4). Sensitivity of the CCI reached 36% (95% 
CI 31% to 40%) and 41% (95% CI 31% to 50%) in deri-
vation and validation cohort, respectively, while specificity 
was 76% (95% CI 73% to 78%) and 75% (95% CI 71% 
to 80%), respectively. The decision curve analysis (online 
supplemental figure S1) indicates a superiority of the 
PCA score compared with the CCI to predict complexity.
AUROCs of PCCL were between those of CCI and PCA 
score with 0.64 (95% CI 0.61 to 0.67) and 0.69 (95% CI 
0.64 to 0.75) in the derivation and validation cohort, 
respectively (table 4). Sensitivity was 52% (95% CI 47% to 
56%) and 61% (95% CI 51% to 70%), respectively, while 
Table 2 PCA score weighted according to coefficients




  ≥80 years Reference
  70–79 years 0.36 (0 to 0.72) 3
  60–69 years 0.5 (0.1 to 0.9) 5
  <60 years 0.94 (0.56 to 1.31) 9
Elective admission 0.36 (0.03 to 0.69) 3
High costs during 
hospitalisation*
  For imaging procedures 0.6 (0.31 to 0.9) 6
  For laboratory analysis 0.77 (0.46 to 1.09) 7
High nurse workload† 0.93 (0.61 to 1.26) 9
Malnutrition‡‡ 0.47 (0.1 to 0.84) 4
Multimorbidity
  No of diagnoses ≤6 Reference
  No of diagnoses >6 and 
<14‡
0.61 (0.25 to 0.96) 6
  No of diagnoses ≥14§ 0.78 (0.36 to 1.2) 7
Medication at admission¶
  Antineoplastic and 
immunomodulating 
agents
0.85 (0.16 to 1.54) 8
  Nervous system 0.33 (0.04, 0.63) 3
Abnormal creatinine level**
  None Reference
  At admission only 0.23 (-0.22 to 0.68) 2
  At admission and 
discharge
0.11 (-0.22 to 0.45) 1
  At discharge only 0.96 (0.29 to 1.63) 9
Leucocytosis††
  None Reference
  At admission only 0.11 (-0.49 to 0.71) 1
  At admission and 
discharge
1.12 (-0.04 to 2.29) 10
  At discharge only 1.68 (0.18 to 3.18) 16
Intercept −2.93 (-3.39 to 2.46) NA
*Defined as costs of all imaging procedures or laboratory analysis 
(without microbiology) during hospital stay above 75th percentile.
†Defined as sum of hours of all nursing work (including sitting guard) 
during hospital stay above 75th percentile.
‡Between 25th and 75th percentile.
§Above 75th percentile.
¶Group of drugs according to ATC classification.
**Defined as serum creatinine ≥100 µmol/L.
††Defined as blood leucocyte count ≥20 G/L.
‡‡ICD10- codes E40 through E46.
ATC, Anatomical Therapeutic Chemical classification system; ICD-10, 
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specificity was 73% (95% CI 71% to 76%) and 75% (95% 
CI 70% to 79%).
DISCUSSION
We derived and validated the PCA score that accurately 
assessed patient complexity in medical inpatients. The 
final score of eleven independent and readily available 
factors, included age, hospital variables, diagnosis- related 
aspects and laboratory variables. The PCA score showed 
overall good performance with a discriminatory power of 
0.78 that surpasses other comorbidity- based tools such as 
the CCI and the PCCL.
In this cohort of medical inpatients, 32% and 24% were 
considered ‘complex’ by the treating physician, in the 
derivation and the validation cohort, respectively. This 
first estimate of patient complexity in the hospital setting 
is consistent with a previous assessment in an outpatient 
population where 26% of total 4302 patients were cate-
gorised as being complex by a primary care physician.1 
Based on these data, the authors later derived a model 
to identify around 20% of 143 372 primary care patients 
as complex. Using the model and outpatient CCI or 
PCCL, only modest agreement between the methods was 
observed (37% and 40%, respectively).2 Therefore, a tool 
not solely based on multimorbidity, such as the newly 
developed PCA score, seems to better identify complex 
patients.
In the present study, age was an inverse indicator of 
complexity. In a previous study of outpatients, mean 
age of complex patients was 60 years vs 48 years in non- 
complex patients.1 Nonetheless, the same study reported 
noteworthy age- related variability: in younger patients 
the association of certain diagnoses (eg, alcohol- related 
diseases) with complexity was stronger, and deprivation as 
contributor to complexity is independent of age.1 5 In our 
setting, discharge planning processes for older patients 
may be better established (eg, including hospital social 
services, decision making based on patient’s provision 
and possibility for indiscriminate discharge to geriatric 
rehabilitation facilities or nursing homes) compared with 
younger patients.1 9 26 27 Treating physicians may there-
fore perceive the discharge planning process of some 
younger patients as difficult and categorise these patients 
as complex. Furthermore, young non- complex patients 
may more often be treated as outpatients or by special-
ist’s clinics instead of our tertiary care general internal 
medicine ward. Elective admissions to a tertiary hospital 
may represent a cohort of rather complex patients prese-
lected by primary care physicians and smaller hospitals 
(21% elective admissions in complex patients vs 14% in 
non- complex patients). The inverse relationship between 
age and complexity, and the relationship between elective 
admissions and complexity may therefore represent struc-
tural incentives to hospitalise complex younger patients 
which overburden outpatient care. It is also possible that 
these patients are only perceived as more complex by the 
treating physician because patients admitted directly to 
the medical ward are pending initial workup otherwise 
provided in the emergency department.
Patients with high costs of imaging procedures may 
reflect the patients with more severe diseases or more 
diagnosis uncertainty. Similarly, high costs for laboratory 
Table 3 Stratification of observed versus predicted complex patients applying the PCA score
Score points Risk category of complexity




Estimated risk of 
complexity
Derivation set <24 Low risk 991 (70) 193 (19) 19
≥24 High risk 416 (30) 254 (61) 61
Validation set <24 Low risk 347 (72) 50 (14) 20
≥24 High risk 135 (28) 66 (49) 62
PCA, Patient Complexity Assessment.









Sensitivity 57 (52 to 61) 57 (47 to 66) 41 (32 to 50) 61 (51 to 70)
Specificity 83 (81 to 85) 81 (77 to 85) 75 (71 to 80) 75 (70 to 79)
Positive predictive value 61 (59 to 66) 49 (40 to 58) 34 (26 to 43) 42 (34 to 50)
Negative predictive value 81 (78 to 83) 86 (81 to 89) 80 (75 to 84) 86 (82 to 90)
Misclassification error 25 (28 to 23) 25 (29 to 21) 33 (37 to 29) 28 (33 to 24)
AUROC 0.77 (0.74 to 0.79)* 0.78 (0.74 to 0.82) 0.62 (0.56 to 0.68) 0.69 (0.64 to 0.75)
*Bootstrap- corrected from internal validation
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analysis may be explained by a higher need of costly or 
repeated measurements in more complex patients. High 
costs for care/nursing were indicators of complexity high-
lighting some concordance between the nurse workload 
and the medical complexity.
In our study multimorbidity (defined as a number of 
more than six diagnoses) was an indicator of complexity. 
Comorbidity- based scores, that is, the CCI, are commonly 
used to identify complex patients. Indeed, in the study of 
Grant et al the proportion of multimorbid patients identi-
fied by a CCI of 2 or more was higher in complex patients, 
that is, 26% of complex patients were multimorbid vs 9% 
of non- complex patients.1 However, many multimorbid 
patients are not complex and not all complex patients are 
multimorbid. In our cohort (derivation and validation 
datasets together) 34% of polymorbid patients (CCI≥2) 
were complex vs 24% in the group of CCI <2. Compa-
rably, nearly one half of patients with a CCI of 2 or greater 
were classified as non- complex in the study of Grant et 
al.1 Therefore, a system to identify complexity should not 
depend on diagnosis alone.
In the PCA score, malnutrition was a risk factor of 
complexity. Malnutrition in hospitalised patients is asso-
ciated with more complications, increased mortality, 
longer hospital stays and higher costs.28 29 Therefore, 
malnutrition and complexity may both reflect a cluster 
of severe and chronic disease as well as socioeconomic 
circumstances.1
Antineoplastic and immunomodulating medication at 
admission was an indicator of complexity. These drugs are 
used for oncologic patients, but also in patients with rheu-
matological disease or after receiving organ transplants. 
These patients may be complex because of challenging 
infectious diseases, end- of- life issues and interdisciplinary 
care. Abnormal values of serum creatinine and leucocyte 
counts at discharge were denoting complexity whether 
the values were normal or abnormal at admission. These 
patients may also requiring more interaction between 
specialists and may complicate the discharge process.
Personal characteristics or mental health issues and 
use of psychoactive medication, that is, narcotics, selec-
tive serotonin reuptake inhibitors, benzodiazepines, 
smoking cessation agents and antipsychotics, have 
been described as characterising complex patients, 
especially in younger patients.1 This is in line with the 
observation that in the PCA score, use of medication 
affecting the nervous system at admission (including 
antipsychotics, mood- stabilisers, sedatives, analgesics 
including opioids, anticonvulsive medication and 
anti- dementia drugs) was an indicator of complexity. 
These patients may challenge the known pathways of 
the healthcare system, for example, by parallel use of 
general internal medicine and psychiatric resources.
There are several limitations of the study. First, we 
used physician’s assessment to define complexity, 
which per definition is subjective. Nonetheless, there 
is no better standard reference (gold standard) and 
the proportion of patients identified as complex was 
similar in previous studies.1 2 Second, the PCA score 
has been developed at a single tertiary hospital in 
Switzerland and therefore may not be generalisable to 
other settings, for example, other health care systems. 
However, costs and nursing workload are not measured 
as absolute values but as those above the 75th percen-
tile, making it transferable to other settings. Also, some 
patients may appear as complex in one setting, while 
they will be judged as non- complex in other settings 
(eg, primary care vs university hospital), nevertheless 
the proportion of complex patients in out setting was 
similar to the one in primary care.1 Therefore, in other 
health systems the final indicators may vary, which 
might be considered when validating the PCA score. 
Third, it is likely that our model does not consider 
every important indicator, but it allows deriving an 
easily usable tool which kept its fair sensitivity and 
good specificity in our external validation. Fourth, the 
PCA score includes values available only at discharge, 
which makes patient- aimed interventions during the 
hospitalisation difficult. This is however also true for 
alternative assessment tools, such as the CCI and the 
PCCL, which had a lower performance in identifying 
complex patients in our cohort. Fifth, imputation of 
missing data may have changed the outcome of the 
study. However, potential predictors with more than 
25% missing data were excluded. Sixth, most of the 
included indicators are not modifiable. For example, 
a patient will still be complex if receiving less imaging 
procedures to reduce costs.
To our knowledge, the PCA score is the first tool 
to identify complex medical patients in the hospital 
setting. It can easily be calculated and is therefore 
predestined to be used for population- based studies 
as it does not involve individual judgement of a physi-
cian. With its prospective design and inclusion of a 
large number of medical inpatients, this study has a 
strong design.
Identification of complex patients by this simple 
tool using electronically available data may help 
monitoring the proportion of complex patients in the 
hospital setting and comparing patient complexity 
level between hospitals. Thereby, the PCA score might 
improve the monitoring of resources distribution 
and coordination of care, for example, by flagging 
complex patients to general practitioners or social 
workers for closer follow- up or low- threshold service.
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 n (%) or median [interquartile range] 
Age    
  ≥ 80 years 447 (32) 337 (35) 110 (25) 
  70 to 79 years 327 (23) 218 (23) 109 (24) 
  60 to 69 years 239 (17) 152 (16) 87 (19) 
  < 60 years 391 (28) 251 (26) 140 (31) 
  Missing 3 (0.2) 2 (0.2) 1 (0.2) 
Gender    
  Male 748 (53) 494 (51) 254 (57) 
  Female 656 (47) 464 (48) 192 (43) 
  Missing  3 (0.2) 2 (0.2) 1 (0.2) 
Living area1    
  Urban 460 (33) 335 (35) 125 (28) 
  Rural 923 (66) 606 (63) 317 (71) 
  Missing 24 (2) 19 (2) 5 (1) 
Marital status    
  Single 477 (34) 306 (32) 171 (38) 
  Couple 673 (48) 458 (48) 215 (48) 
  Widowed 252 (18) 193 (20) 59 (13) 
  Missing 5 (0.4) 3 (0.3) 2 (0.4) 
Hospitalization within last 12 months 480 (34) 317 (33) 163 (36) 
Medication2    
  Antineoplastic and immunomodulating agents at 
admission 
43 (3) 20 (2) 23 (5) 
  Nervous system at admission 1001 (71) 666 (69) 335 (75) 
  Systemic hormonal preparations, excluding sex 
hormones and insulins at discharge 
253 (18) 163 (17) 90 (20) 
High costs during hospitalization3    
  For imaging procedures 367 (26) 179 (19) 188 (42) 
  For laboratory analysis 365 (26) 147 (15) 218 (49) 
High nurse workload4 358 (25) 146 (15) 212 (47) 
Charlson Comorbidity Index 2 [0; 4] 2 [0; 3] 2.5 [1; 5] 
Principal or concomitant diagnosis at discharge    
  Cancer5 175 (12) 104 (11) 71 (16) 
  COPD6 139 (10) 91 (9) 48 (11) 
  Dementia7 120 (8) 89 (9) 31 (7) 
  Depression8 148 (10) 94 (10) 54 (12) 
  Heart failure9 235 (17) 143 (15) 92 (21) 
                                               
1 Defined according to the Swiss Federal Statistical Office based on place of residence 
2 Group of drugs according to ATC classification 
3 Defined as costs of all imaging procedures or medication during hospital stay above 75th percentile 
4 Defined as sum of hours of all nursing work (incl. sitting guard) during hospital stay above 75th percentile 
5 ICD10-codes B21, C00 through C97, Z03.1 
6 ICD10-codes J44 
7 ICD10-codes F00 through F03, F05.0, F05.1 
8 ICD10-codes F20.4, F25.1, F31.3 F31.4, F31.5, F32, F33, F41.2, F92.0 
9 ICD10-codes I50 
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  Pneumonia10 186 (13) 115 (12) 71 (16) 
  Sepsis11 162 (11) 88 (9) 74 (17) 
  Stroke12 72 (5) 50 (5) 22 (5) 
  Substance abuse13 154 (11) 90 (9) 64 (14) 
  Syncope14 68 (5) 55 (6) 13 (3) 
  Malnutrition15 190 (13) 82 (8) 108 (24) 
Multimorbidity    
  Low (number of diagnoses ≤ 6) 387 (27) 322 (33) 65 (14) 
  Middle (number of diagnoses > 6 and <14)16 642 (46) 443 (46) 199 (44) 
  High (number of diagnoses ≥ 14) 375 (27) 193 (20) 182 (41) 
PCCL    
  No complication or comorbidity 297 (21) 239 (25) 58 (13) 
  Light complication or comorbidity 22 (2) 15 (2) 7 (2) 
  Moderate complication or comorbidity 211 (15) 161 (17) 50 (11) 
  Severe complication or comorbidity 390 (28) 289 (30) 101 (23) 
  Very severe complication or comorbidity 484 (34) 254 (26) 230 (51) 
  Missing 3 (0.2) 2 (0.2) 1 (0.2) 
Abnormal creatinine level17    
  At admission and discharge 278 (20) 181 (19) 97 (22) 
  At admission only 128 (9) 72 (7) 56 (12) 
  At discharge only 50 (4) 24 (2) 26 (6) 
  Missing 275 (19) 229 (24) 46 (10) 
Leukocytosis18    
  At admission and discharge 15 (1) 6 (0.6) 9 (2) 
  At admission only 60 (4) 35 (4) 25 (6) 
  At discharge only 11 (0.8) 3 (0.3) 8 (2) 
  Missing 260 (18) 223 (23) 37 (8) 
Patient destination    
  Death 105 (7) 73 (8) 32 (7) 
  Home 875 (62) 621 (65) 254 (57) 
  Hospital 141 (10) 85 (9) 56 (12) 
  Nursing home 109 (8) 79 (8) 30 (7) 
  Rehabilitation 138 (10) 79 (8) 59 (13) 
  Others and missing 39 (3) 23 (2) 16 (4) 
 








 n (%) or median [interquartile range] 
Age    
  ≥ 80 years 132 (27) 105 (29) 27 (23) 
                                               
10 ICD10-codes A48.1, B01.2, B05.2, J10.0, J11.0, J12 through J18, J68.0, J69, J85.1, O74.0, U69.00 
11 ICD10-codes A02.1, A20.7, A22.7, A26.7, A32.7, A39.2, A39.3, A39.4, A40, A41, A42.7, B37.7 
12 ICD10-codes I63 
13 ICD10-codes F10 through F19, F53, F66.8, F66.9 
14 ICD10-codes R55 
15 ICD10-codes E40 through E46 
16 Between 25th and 75th percentile 
17 Defined as creatinine ≥100 µmol/l 
18 Defined as leukocyte count ≥20 G/l 
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  70 to 79 years 110 (23) 86 (23) 24 (21) 
  60 to 69 years 83 (17) 59 (16) 24 (21) 
  < 60 years 146 (30) 112 (31) 34 (29) 
  Missing 11 (2) 4 (1) 7 (6) 
Gender    
  Male 254 (53) 199 (54) 55 (47) 
  Female 217 (45) 163 (44) 54 (47) 
  Missing  11 (2) 4 (1) 7 (6) 
Living area1    
  Urban 151 (31) 118 (32) 33 (28) 
  Rural 315 (65) 242 (66) 73 (63) 
  Missing 16 (3) 6 (2) 10 (9) 
Marital status    
  Single 159 (33) 123 (34) 36 (31) 
  Couple 243 (50) 183 (50) 60 (52) 
  Widowed 79 (16) 59 (16) 20 (17) 
  Missing 1 (0.2) 1 (0.3) 0 (0) 
Hospitalization within last 12 months 193 (40) 135 (37) 58 (50) 
Medication2    
  Antineoplastic and immunomodulating agents at 
admission 
27 (6) 18 (5) 9 (8) 
  Nervous system at admission 339 (70) 252 (69) 87 (75) 
  Systemic hormonal preparations, excluding sex 
hormones and insulins at discharge 
105 (22) 73 (20) 32 (28) 
High costs during hospitalization3    
  For imaging procedures 118 (24) 76 (21) 42 (36) 
  For laboratory analysis 117 (24) 56 (15) 61 (53) 
High nurse workload4 117 (24) 57 (15.6) 60 (52) 
Charlson Comorbidity Index 2 [0; 4] 2.00 [0; 3] 3 [1; 5] 
Principal or concomitant diagnosis at discharge    
  Cancer5 50 (10) 50 (10) 50 (10) 
  COPD6 32 (9) 32 (8) 32 (9) 
  Dementia7 18 (15) 18 (15) 18 (15) 
  Depression8 47 (10) 47 (10) 47 (10) 
  Heart failure9 33 (9) 33 (9) 33 (9) 
  Pneumonia10 14 (12) 14 (12) 14 (12) 
  Sepsis11 43 (9) 43 (9) 43 (9) 
  Stroke12 36 (10) 36 (9) 36 (10) 
  Substance abuse13 7 (6) 7 (6) 7 (6) 
  Syncope14 61 (13) 61 (13) 61 (13) 
                                               
1 Defined according to the Swiss Federal Statistical Office based on place of residence 
2 Group of drugs according to ATC classification 
3 Defined as costs of all imaging procedures or medication during hospital stay above 75th percentile 
4 Defined as sum of hours of all nursing work (incl. sitting guard) during hospital stay above 75th percentile 
5 ICD10-codes B21, C00 through C97, Z03.1 
6 ICD10-codes J44 
7 ICD10-codes F00 through F03, F05.0, F05.1 
8 ICD10-codes F20.4, F25.1, F31.3 F31.4, F31.5, F32, F33, F41.2, F92.0 
9 ICD10-codes I50 
10 ICD10-codes A48.1, B01.2, B05.2, J10.0, J11.0, J12 through J18, J68.0, J69, J85.1, O74.0, U69.00 
11 ICD10-codes A02.1, A20.7, A22.7, A26.7, A32.7, A39.2, A39.3, A39.4, A40, A41, A42.7, B37.7 
12 ICD10-codes I63 
13 ICD10-codes F10 through F19, F53, F66.8, F66.9 
14 ICD10-codes R55 
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  Malnutrition15 46 (13) 46 (13) 46 (13) 
Multimorbidity    
  Low (number of diagnoses ≤ 6) 123 (25) 113 (31) 10 (9) 
  Middle (number of diagnoses > 6 and <14)16 199 (41) 160 (44) 39 (34) 
  High (number of diagnoses ≥ 14) 149 (31) 89 (24) 60 (52) 
PCCL    
  No complication or comorbidity 83 (1) 73 (20) 10 (9) 
  Light complication or comorbidity 7 (1) 6 (2) 1 (0.9) 
  Moderate complication or comorbidity 81 (17) 72 (20) 9 (8) 
  Severe complication or comorbidity 143 (30) 120 (33) 23 (20) 
  Very severe complication or comorbidity 157 (33) 91 (24) 66 (57) 
  Missing 11 (2) 4 (1) 7 (6) 
Abnormal creatinine level17    
  At admission and discharge 90 (19) 60 (16) 30 (26) 
  At admission only 54 (11) 34 (9) 20 (17) 
  At discharge only 13 (2.7) 10 (3) 3 (3) 
  Missing 89 (18) 82 (22) 7 (6) 
Leukocytosis18    
  At admission and discharge 4 (0.8) 2 (0) 2 (2) 
  At admission only 17 (3) 12 (3) 5 (4) 
  At discharge only 2 (0.4) 2 (0.5) 0 (0) 
  Missing 91 (19) 83 (23) 8 (7) 
Patient destination    
  Death 134 (7) 91 (7) 43 (8) 
  Home 1178 (62) 873 (66) 305 (54) 
  Hospital 191 (10) 119 (9) 72 (13) 
  Nursing home 155 (8) 108 (8) 47 (8) 
  Rehabilitation 171 (9) 101 (8) 70 (12) 
  Others and missing 60 (3) 34 (3) 26 (5) 
 
                                               
15 ICD10-codes E40 through E46 
16 Between 25th and 75th percentile 
17 Defined as creatinine ≥100 µmol/l 
18 Defined as leukocyte count ≥20 G/l 
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Supplementary figure S1. Decision curve analysis. A, derivation dataset. B, validation dataset. 




BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open





BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-041205:e041205. 11 2021;BMJ Open, et al. Liechti FD
3 
Supplementary figure S2. A, PCA score, derivation dataset. B, PCA score, validation dataset. 
C, PCCL, derivation dataset. D, PCCL, validation dataset. E, CCI, derivation dataset. F, CCI, 
validation dataset. 
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